The (un)changing face of TiPS.
Adam Smith
pág. 1
pág. 2
Pharmacogenetics and pharmacogenomics: tailored drug therapy for the 21st century.: tailored drug therapy for the 21st century.
Struan F. A. Grant
pág. 3
P2 receptors meet the immune system.
Francesco Di Virgilio, Pier Andrea Borea
pág. 5
Glutamate receptor channel signatures.
Rolf Sprengel, Rachel Aronoff
pág. 7
The dark side of a 'detoxification' mechanism.
Elizabeth M. J. Gillam
pág. 11
pág. 11
Adam Smith, E. K.
pág. 12
pág. 13
The ligand that came from within.
Daniele Piomelli
pág. 17
Ceramide: a new second messenger of cannabinoid action.: a new second messenger of cannabinoid action.
Manuel Guzman, Ismael Galve Roperh
pág. 19
In silico research in drug discovery.
Georg C. Terstappen, Angelo Reggiani
pág. 23
Involvement of Na[sup +] channels in pain pathways.
Mark D. Baker, John N. Wood
pág. 27
Yuko Fukata, Mutsuki Amano
pág. 32
Airway goblet-cell mucus secretion.
Alan D. Jackson
pág. 39
Carlsson and the discovery of dopamine.
Francine M. Benes
pág. 46
Of mice and men (or at least of their behavior).
Gerard R. Dawson
pág. 47
CGRP '98: you attended the conference, now read the book!: you attended the conference, now read the book!
Joy P. Hinson
pág. 48
'Atypical' antipsychotics: how far have we come?: how far have we come?
pág. 49
© 2001-2024 Fundación Dialnet · Todos los derechos reservados